Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors
Status:
Completed
Trial end date:
2016-10-05
Target enrollment:
Participant gender:
Summary
Curcumin is an extract of the tumeric root that has been shown to have anti-tumor properties
in laboratory studies. Curcumin, and its parent spice, turmeric (curcuma longa), are the 4th
most commonly purchased dietary supplement in the U.S. Many cancer patients take curcumin
during their treatment for cancer because of the purported health benefits.
This research study is designed to learn more about the safety, pharmacokinetics and
effectiveness of irinotecan when given in combination with curcumin in patients with
metastatic colorectal cancer. The study of how the body absorbs, processes and eliminates
drugs is called pharmacokinetics (PK). One of the main purposes of this study is to better
understand the interaction between curcumin and irinotecan by measuring levels of irinotecan
in the blood (ie. measure irinotecan PK) when a patient also takes curcumin. Information
collected from this study could result in improved dosing guidelines and lead to more
effective treatment of your cancer with less toxicity.